Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599384 · ClinicalTrials.gov registry record
Emulation of the RECORD3 Trial Using Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 149,248
- Enrollment target
NCT07599384: Completed study, sponsored by Brigham and Women's Hospital.
NCT07599384 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 149,248 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07599384 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 149,248 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real-world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real-world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
The primary outcome is the time from 1 day after prescription fill of the exposure or comparator to the first occurrence of any component of the composite endpoint: deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 17 days after elective total knee arthroplasty, comparing rivaroxaban versus enoxaparin.
Interventions
- DRUG Enoxaparin
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149,248 participants |
| Start Date | 2024-10-13 |
| Est. Completion | 2026-06-15 |
What the finished NCT07599384 record still lists
NCT07599384 is an observational study that tracks outcomes without assigning an intervention. Its 149,248 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT07599384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07599384 about?
NCT07599384 is a clinical study titled "Emulation of the RECORD3 Trial Using Healthcare Claims Data". Investigators are building an empirical evidence base for real-world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real-world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT07599384?
This trial is currently completed. The enrollment target is 149,248 participants. The study started on 2024-10-13. Estimated completion is 2026-06-15.
What interventions are being tested in trial NCT07599384?
The interventions under investigation include: Enoxaparin (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT07599384?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI